Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H15N2O2.Cl |
| Molecular Weight | 182.649 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)CCOC(N)=O
InChI
InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
| Molecular Formula | C6H15N2O2 |
| Molecular Weight | 147.1955 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL220 |
6.0 mM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | MIOSTAT Approved UseIntraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery. Launch Date1972 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Avoidance learning: long-lasting deficits after temporal lobe seizure. | 1969 Dec 12 |
|
| Sustained atrial fibrillation induced by carbachol, methacholine and bethanechol. | 1971 Apr |
|
| Motor disturbances produced by intrastriatal injection of cyclic AMP and cyclic GMP. | 1976 Nov |
|
| Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens. | 1984 Oct |
|
| Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". | 1984 Sep 3 |
|
| Neuropeptide Y and calcitonin gene-related peptide: effects on glucagon and insulin secretion in the mouse. | 1987 |
|
| Cardiovascular effects of cholinergic agents in the ventral-lateral midbrain periaqueductal gray of the rat. | 1987 Dec |
|
| Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. | 1987 Mar |
|
| The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior. | 1988 Feb 16 |
|
| Renal function during onset of carbachol-induced hypertension in conscious rats. | 1990 |
|
| Similarities between the akinesia induced by carbachol microinjections into the pontine reticular formation and neuroleptic catalepsy. | 1992 |
|
| Sites at which neuropeptide Y modulates parasympathetic control of heart rate in guinea pigs and rats. | 1992 May 1 |
|
| Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype. | 2000 Aug |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia. | 2002 Nov |
|
| Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. | 2003 Aug 22 |
|
| Impaired gastric secretion and lack of trophic responses to hypergastrinemia in M3 muscarinic receptor knockout mice. | 2003 Dec |
|
| Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. | 2003 Dec |
|
| Pharmacological characterization of recombinant bovine alpha3beta4 neuronal nicotinic receptors stably expressed in HEK 293 cells. | 2003 Jun 12 |
|
| Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. | 2005 Jun |
|
| Theoretical and experimental investigation of calcium-contraction coupling in airway smooth muscle. | 2006 |
|
| Gene transfer of neuronal nitric oxide synthase into intracardiac Ganglia reverses vagal impairment in hypertensive rats. | 2007 Feb |
|
| Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells. | 2008 Jul |
|
| Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. | 2008 Sep 25 |
|
| Muscarinic receptors prevent oxidative stress-mediated apoptosis induced by domoic acid in mouse cerebellar granule cells. | 2009 Apr |
|
| Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. | 2009 Aug |
|
| Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. | 2010 Aug |
|
| Structural and functional effects of developmental exposure to ethanol on the zebrafish heart. | 2010 Jun |
|
| Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase. | 2010 Sep 6 |
|
| TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011 Feb 18 |
Patents
Sample Use Guides
MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration:
Other
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:00 GMT 2023
by
admin
on
Fri Dec 15 15:11:00 GMT 2023
|
| Record UNII |
8Y164V895Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-ATC |
S01EB02
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-ATC |
N07AB01
Created by
admin on Fri Dec 15 15:11:00 GMT 2023 , Edited by admin on Fri Dec 15 15:11:00 GMT 2023
|
||
|
NDF-RT |
N0000175884
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-VATC |
QS01EB02
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
||
|
WHO-VATC |
QA03AB92
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5831
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
C47430
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
DB00411
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
32865
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
488
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
SUB06087MIG
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
298
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
m3051
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
D002217
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL965
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
DTXSID9022730
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
3385
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
51-83-2
Created by
admin on Fri Dec 15 15:11:00 GMT 2023 , Edited by admin on Fri Dec 15 15:11:00 GMT 2023
|
PRIMARY | |||
|
6373
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
1092009
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
1999
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
383
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
Carbachol
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
100000081628
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
200-127-3
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY | |||
|
Carbachol
Created by
admin on Fri Dec 15 15:11:01 GMT 2023 , Edited by admin on Fri Dec 15 15:11:01 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Duration of Action | PHARMACOKINETIC |
|
INTRAOCULAR ADMINISTRATION PHARMACOKINETIC |
|
||